美托洛尔联合瑞舒伐他汀治疗老年冠心病并室性心律失常临床研究  

China Pharmaceuticals Clinical Observation of Metoprolol Combined with Rosuvastatin in the Treatment of Elderly Coronary Heart Disease Complicated with Ventricular Arrhythmia

作　　者：徐锋 陆叶[1] XU Feng;LU Ye(Jiangyin People's Hospital,Wuxi,Jiangsu,China 214400)

机构地区：[1]江苏省江阴市人民医院,江苏无锡214400

出　　处：《中国药业》2024年第2期100-104,共5页China Pharmaceuticals

基　　金：江苏省老年健康科研项目[LD2021034]。

摘　　要：目的探讨美托洛尔联合瑞舒伐他汀治疗老年冠状动脉粥样硬化性心脏病(简称冠心病)并室性心律失常的临床疗效。方法选取医院2020年1月至2023年2月收治的冠心病并室性心律失常老年患者98例,按随机数字表法分为观察组和对照组,各49例。两组患者均予利尿剂、血管扩张剂、抗血小板聚集药物等基础治疗,并口服瑞舒伐他汀钙片,观察组患者加服琥珀酸美托洛尔缓释片。两组患者均连续治疗3个月。结果观察组总有效率为95.92%,显著高于对照组的81.63%(P<0.05)。与治疗前比较,两组患者治疗后的室性期前收缩、成对室性期前收缩、短期阵发室性心动过速发作次数24 h内均显著减少,左心室射血分数显著升高,左心室舒张末期内径、左心室收缩末期内径均显著缩短(P<0.05);血管内皮生长因子、一氧化氮水平均显著升高,内皮素-1、可溶性生长刺激表达基因2蛋白、心肌肌钙蛋白I、N末端脑钠肽前体水平均显著降低(P<0.05);肿瘤坏死因子-α、髓过氧化物酶、超敏C反应蛋白、低密度脂蛋白胆固醇、甘油三酯、总胆固醇水平均显著降低,高密度脂蛋白胆固醇水平均显著升高(P<0.05);三水平五维健康量表中视觉模拟量表评分显著升高(P<0.05)。观察组以上指标改善幅度均显著大于对照组(P<0.05)。观察组与对照组不良反应发生率相当(12.24%比10.20%,P>0.05)。结论美托洛尔联合瑞舒伐他汀治疗老年冠心病并室性心律失常,能减少室性心律失常的发作次数,改善心功能、血管内皮功能及血脂水平,抑制心肌损伤及炎性反应,提高患者的生活质量。Objective To investigate the clinical efficacy of metoprolol combined with rosuvastatin in the treatment of elderly coronary heart disease(CHD)complicated with ventricular arrhythmia.Methods A total of 98 elderly patients with CHD and ventricular arrhythmia admitted to the hospital from January 2020 to February 2023 were selected and divided into the observation group and the control group by the random number table method,with 49 cases in each group.The patients in the two groups were given basic treatments(diuretics,vasodilators,anti-platelet aggregation drugs)and Rosuvastatin Calcium Tablets(orally),on this basis,the patients in the observation group were given Metoprolol Succinate Sustained-Release Tablets(orally).Both groups were treated continuously for three months.Results The total effective rate in the observation group was 95.92%,which was significantly higher than 81.63%in the control group(P<0.05).Compared with those before treatment,the frequencies of ventricular premature beat,paired ventricular premature beat and short-term paroxysmal ventricular tachycardia in the two groups significantly decreased after treatment,the left ventricular ejection fraction(LVEF)significantly increased,the left ventricular end-diastolic diameter(LVEDd)and left ventricular end-systolic diameter(LVESd)significantly shortened(P<0.05).Compared with those before treatment,the vascular endothelial growth factor(VEGF)and nitric oxide(NO)levels in the two groups significantly increased after treatment,the endothelin-1(ET-1),soluble growth stimulation expressed gene 2 protein(sST2),cardiac troponin I(cTnI)and N-terminal pro-brain natriuretic peptide(NT-proBNP)levels significantly decreased(P<0.05).Compared with those before treatment,the tumor necrosis factor-α(TNF-α),myeloperoxidase(MPO),hypersensitive C-reactive protein(hs-CRP),low density lipoprotein cholesterol(LDL-C),triglyceride(TG)and total cholesterol(TC)levels in the two groups significantly decreased after treatment,and the high density lipoprotein cholesterol(HDL-C

关 键 词：美托洛尔 瑞舒伐他汀 冠状动脉粥样硬化性心脏病 室性心律失常 老年患者 临床疗效 

分 类 号：R969.4[医药卫生—药理学] R541.4[医药卫生—药学]